Integrated DNA Technologies, Inc. — Cyborg Score 8/10

Strong
Oligonucleotide synthesis and genomic reagents

Strategic Profile

In April 2026, IDT announced the expansion of its manufacturing footprint in Coralville, Iowa, delivering a more than threefold increase in synthesis capacity to support next-generation sequencing (NGS)-based oncology workflows, including minimal residual disease (MRD) applications. In March 2026, the company announced its entry into the clinical diagnostics market with the launch of its first in vitro diagnostic (IVD) NGS assay solutions. This dual focus on manufacturing scale and clinical market expansion positions IDT as a key enabler in precision oncology diagnostics.

Cyborg Score Rationale

IDT demonstrates strong operational momentum with major capacity expansion (3x increase), entry into regulated clinical diagnostics, and growing revenue ($650M in 2026). Backed by Danaher's resources, the company holds significant competitive advantages in oligonucleotide synthesis and NGS applications. However, private ownership and limited disclosed profitability details constrain full visibility.

Top Insights

  • (April 2026) Expanded Coralville manufacturing capacity threefold to support growing MRD and NGS-based oncology workflows
  • (March 2026) Launched first in vitro diagnostic (IVD) NGS assay solutions (Archer FUSIONPlex-HT Dx, VARIANTPlex-HT Dx), marking strategic shift into regulated clinical diagnostics
  • (Early 2026) Introduced new NGS innovation roadmap targeting cancer research bottlenecks in library preparation and variant detection
  • Private subsidiary of Danaher with $650M revenue (2026) and ~1,560 employees globally, serving 100+ countries

Named Competitors

  • Twist Bioscience — Synthetic biology and DNA synthesis platform for research and diagnostics
  • Eurofins Genomics — Custom DNA/RNA synthesis and genomics services
  • Illumina NovaSeq / NextSeq — Next-generation sequencing instruments and clinical genomics platforms
  • Applied Biosystems / Thermo Fisher — Life sciences tools including PCR, NGS, and genomics reagents

Recent Developments

  • (April 2026) Manufacturing expansion in Coralville with 3x synthesis capacity increase for MRD and oncology NGS workflows
  • (March 2026) Entry into clinical diagnostics market with FDA/CE-mark IVD offerings for gene fusion and variant detection
  • (Early 2026) Released NGS innovation roadmap addressing library preparation, variant sensitivity, and whole genome research

Open the full interactive Integrated DNA Technologies, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →